SOLTAMOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLTAMOX (SOLTAMOX).
Selective estrogen receptor modulator (SERM). Binds to estrogen receptors, competitively inhibiting estrogen binding. In breast tissue, acts as an antagonist; in bone and cardiovascular system, acts as an agonist.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to active metabolites (e.g., endoxifen, 4-hydroxytamoxifen). Also undergoes glucuronidation via UGT1A4 and UGT2B7. |
| Excretion | Primarily renal (80-90% as unchanged drug); biliary/fecal excretion accounts for 10-20%. |
| Half-life | 24-36 hours in adults; prolonged in renal impairment (up to 96 hours in ESRD). Steady-state reached in ~5 days. |
| Protein binding | 98-99%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.8 L/kg; indicates extensive tissue distribution, including into breast milk. |
| Bioavailability | Oral: 70-80% (first-pass metabolism minimal). |
| Onset of Action | Oral: 2-4 hours for peak plasma concentration; IV: immediate onset of action. |
| Duration of Action | 24-48 hours based on once-daily dosing; clinical effect persists due to long half-life. |
300 mg orally once daily for 5 days, starting on day 1 of menses.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR 30-89 mL/min). Not recommended for severe renal impairment (eGFR <30 mL/min) due to lack of data. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Use with caution in moderate hepatic impairment (Child-Pugh class B); dose reduction has not been established. No adjustment needed for mild impairment (Child-Pugh class A). |
| Pediatric use | Not indicated for premenarcheal patients; safety and efficacy not established in children. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to potential age-related renal and hepatic function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOLTAMOX (SOLTAMOX).
| Breastfeeding | Tamoxifen is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.5–1.0. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. |
| Teratogenic Risk | SOLTAMOX (tamoxifen) is contraindicated in pregnancy (FDA Pregnancy Category D). First trimester exposure is associated with fetal anomalies including craniofacial defects, genital tract abnormalities, and developmental delay. Second and third trimester exposure may increase risk of spontaneous abortion, premature birth, and low birth weight. Animal studies show teratogenicity at doses lower than human therapeutic doses. |
■ FDA Black Box Warning
WARNING: Serious and life-threatening events associated with tamoxifen include uterine malignancies (endometrial adenocarcinoma, uterine sarcoma), stroke, and pulmonary embolism. The risk increases with duration of use and is higher in patients with certain risk factors. Use only if benefit outweighs risk.
| Serious Effects |
History of thromboembolic events (DVT, PE); history of stroke; hypersensitivity to tamoxifen or any component; patients requiring concurrent warfarin therapy (relative); pregnancy; breastfeeding (relative).
| Precautions | Increased risk of uterine cancer (endometrial cancer, uterine sarcoma); increased risk of thromboembolic events (DVT, PE, stroke); hepatic effects (fatty liver, hepatitis, cholestasis); hypercalcemia in patients with bone metastases; ocular effects (cataracts, retinopathy); fetal harm (pregnancy category D); drug interactions with CYP2D6 inhibitors or inducers. |
Loading safety data…
| Fetal Monitoring | If pregnancy occurs during treatment, immediate discontinuation and fetal assessment are required. Regular monitoring includes: pregnancy test prior to initiation and monthly during therapy; ultrasonography for fetal anatomy if exposure occurs; monitoring for signs of fetal distress or growth restriction. Maternal monitoring for thromboembolic events, hepatic effects, and endometrial changes is also necessary. |
| Fertility Effects | Tamoxifen may induce ovulation and increase fertility in premenopausal women due to its antiestrogenic effects on the hypothalamus-pituitary axis. Long-term use may cause ovarian cysts, infertility from premature ovarian failure (especially in younger women), and menstrual irregularities. In men, tamoxifen can impair spermatogenesis and reduce fertility. |